= Solution
The most informative difference is phosphorylation without <PDGF>, relative to sample A. The following are candidate interpretations of the supplied <Western blot>, not definitive clinical diagnoses or protein identifications:
* \b[B: evidence consistent with constitutive signaling in the <phosphoinositide 3-kinase>–<Akt> branch.] A basal band near $62\,\mathrm{kDa}$ is compatible with <Akt>, while the apparent <Raf> and <MEK>/<ERK> bands still require stimulation.
* \b[C: evidence consistent with constitutive <Raf>–<MEK>–<ERK> pathway output.] The basal $44$–$45\,\mathrm{kDa}$ band is compatible with <MEK> or <ERK>; basal <Raf> phosphorylation is not evident, so the lesion need not be in <Raf> itself.
* \b[D: evidence consistent with excess signaling in both branches.] Basal bands compatible with <Raf>, <Akt> and <MEK>/<ERK> resemble the stimulated healthy pattern.
* \b[E: an abnormal pattern requiring further identification.] The additional bands near $85$ and $35\,\mathrm{kDa}$ are constitutive. The larger could be the <PI3K regulatory subunit p85>, making altered <phosphoinositide 3-kinase> signaling a candidate, but basal <Akt> and <MEK>/<ERK> outputs are not clearly increased. Neither mass matching nor phosphorylation of a regulatory subunit alone proves pathway activation or a <Rasopathy>.
* \b[F: no excess signaling is demonstrated under these conditions.] Its basal and induced patterns resemble A; this single assay cannot exclude every possible <Rasopathy> mechanism.
A single broad phospho-<antibody> cannot reliably distinguish the closely sized <MEK> and <ERK> bands or determine whether any phosphorylation site is activating. Clinical assessment and genetic and functional confirmation remain necessary.
Back to article page
